The Imaging Core is an integral component of this Program Project and will conduct all of the in vivo imaging studies in experimental animal models. The main objective of using non-invasive molecular-genetic imaging in this Program Project is to assess the spatial and temporal dynamics of stem cell trafficking and engraftment, as well as T cell trafficking and lymphoid and myeloid tumor cell targeting. The Imaging Core will utilize several dedicated pre-clinical and clinical imaging instruments, including: bioluminescence imaging (BLI) system, pre-clinical micro-PET/CT for imaging in mice, clinical PET/CT system for imaging non-human primates, Radiochemistry Facilitiy, and Reporter Vecotr Laboraotury of the Dept. of Experimental Diagnostic Imaging (EDI), UT-MDACC. Specifically, for Project 1, the Core will perform repetitive imaging studies to compare spatial-temporal dynamics of engraftment: a) in NOG/SCID mice of two different human cord blood-derived CD34+ hematopoietic stem cell populations (CB-HSC) differentially labeled with FLuc and RLuc reporter genes for BLI: 1) CB-HSC from two unmanipulated cords;2) unmanipulated vs in vitro expanded CB-HSC, and 3) CB-HSC unmanipulated and expanded with/without fucosylation to improve homing to the bone marrow. For Project III, the Core will perform: a) BLI and 18F-FEAU microPET/CT in NOG/SCID mice to assess spatial-temporal dynamics of trafficking of HSV1-tk/Luc-labeled CB-derived T cells expressing CD19-specific chimeric antigen receptor (CAR+) and compare to that of the CB-derived tri-virus-specific (CD19)CAR+ T cells;b) repetitive PET/CT with 18F-FEAU in rhesus macaques to non-invasively monitor the trafficking and homing of adoptively transferred autologous T lymphocytes expressing HSV1-tk reporter gene and CD19-specific or CD20-specific CARs. For Project IV, the Core will use BLI and microPET/CT to assess the distribution, expansion, and persistence in mice of (1) human AML labeled with RLuc/RFP reporter, (2) high affinity PR1-CTL, and (3) low affinity PR1-CTL labeled with HSVI-tk/FLuc reporter gene. In summary, BLI will enable cost-effective high-throughput studies in mice, while 18F-FEAU PET/CT in mice and nonhuman primates will facilitate transition of the proposed cellular therapies into the clinic.

Public Health Relevance

The Imaging Core is an integral component of this Program Project and will conduct all of the in vivo imaging studies in experimental animal models. The main objective of using non-invasive molecular-genetic imaging in this Program Project is to assess the spatial and temporal dynamics of stem cell trafficking and engraftment, as well as T cell trafficking and lymphoid and myeloid tumor cell targeting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA148600-03
Application #
8567117
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
3
Fiscal Year
2013
Total Cost
$162,825
Indirect Cost
$38,383
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Kellner, Joshua; Li, Sufang; Zweidler-McKay, Patrick A et al. (2015) Phenotypic and functional comparison of mobilized peripheral blood versus umbilical cord blood megakaryocyte populations. Cytotherapy 17:418-27
Deniger, Drew C; Maiti, Sourindra N; Mi, Tiejuan et al. (2014) Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 20:5708-19
Parmar, Simrit; Liu, Xiaoying; Tung, Shawndeep S et al. (2014) Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy 16:90-100
Kumaresan, Pappanaicken R; Manuri, Pallavi R; Albert, Nathaniel D et al. (2014) Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A 111:10660-5
Hildebrandt, Martin; Peggs, Karl; Uharek, Lutz et al. (2014) Immunotherapy: opportunities, risks and future perspectives. Cytotherapy 16:S120-9
Mehta, Rohtesh S; Di Stasi, Antonio; Andersson, Borje S et al. (2014) The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk 14:e1-5
Hanley, Patrick J; Bollard, Catherine M (2014) Controlling cytomegalovirus: helping the immune system take the lead. Viruses 6:2242-58
Bear, Adham S; Hanley, Patrick J; Bosque, Doyle M et al. (2014) Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy 16:1153-7
Saglio, Francesco; Hanley, Patrick J; Bollard, Catherine M (2014) The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy 16:149-59
Robinson, Simon N; Thomas, Michael W; Simmons, Paul J et al. (2014) Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 16:84-9

Showing the most recent 10 out of 19 publications